ABSTRACT
I. INTRODUCTION Patients undergoing high-or multiple-dose chemotherapies suffer periods of cytopenia which can be associated with infectious diseases, bleeding episodes, and other treatmentrelated complications. The use of cytokine-mobilized peripheral blood progenitor cell (PBPC) populations has significantly shortened such cytopenic periods. It has not completely eliminated them, however, especially in patients who have undergone multiple rounds of chemotherapy (1-4). It has been hypothesized that infusion of maturing populations of hematopoietic cells along with reconstituting grafts may minimize the magnitude and/or duration of these cytopenias (4-14).
